Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Avalon GloboCare Corp. (ALBT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/07/2025: ALBT (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -77.1% | Avg. Invested days 44 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 11/07/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 5.93M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 0.02 | 52 Weeks Range 2.11 - 11.66 | Updated Date 06/29/2025 |
52 Weeks Range 2.11 - 11.66 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -8.01 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -243.34% |
Management Effectiveness
Return on Assets (TTM) -23.8% | Return on Equity (TTM) -833.99% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 25157592 | Price to Sales(TTM) 7.34 |
Enterprise Value 25157592 | Price to Sales(TTM) 7.34 | ||
Enterprise Value to Revenue 18.38 | Enterprise Value to EBITDA -4.45 | Shares Outstanding 2132240 | Shares Floating 1451691 |
Shares Outstanding 2132240 | Shares Floating 1451691 | ||
Percent Insiders 23.35 | Percent Institutions 0.83 |
Upturn AI SWOT
Avalon GloboCare Corp.
Company Overview
History and Background
Avalon GloboCare Corp. is a biopharmaceutical company focused on developing and commercializing cell-based technologies and therapeutics. Founded to advance innovative healthcare solutions.
Core Business Areas
- Cellular Immunotherapy: Developing allogeneic cell-based immunotherapies for cancer and other diseases.
- Exosome Technology: Utilizing exosome technology for drug delivery and diagnostics.
- Stem Cell Technology: Application of stem cell technologies to regenerative medicine and disease treatment.
Leadership and Structure
The leadership team consists of experienced professionals in biopharmaceuticals, medicine, and business. The organizational structure is typical of a publicly traded biopharmaceutical company.
Top Products and Market Share
Key Offerings
- AVA-011: A CAR-T therapy product candidate for B-cell acute lymphoblastic leukemia (B-ALL). Market share is currently developmental and not yet commercialized. Competitors include Novartis (Kymriah) and Gilead (Yescarta).
- ACTEX(TM): ACTEX(TM) is an exosome-based diagnostic and therapeutic platform. Market share is in early stages. Competitors include Evox Therapeutics and Codiak BioSciences.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high research and development costs, stringent regulatory requirements, and intense competition. Advancements in cell and gene therapies are driving growth.
Positioning
Avalon GloboCare is positioning itself as an innovator in cell-based immunotherapies and exosome technology. The company is competing with larger pharmaceutical companies and specialized biotech firms.
Total Addressable Market (TAM)
The total addressable market for cell and gene therapies is estimated to reach billions of dollars. Avalon GloboCare is positioned to capture a share of this market through its innovative technologies.
Upturn SWOT Analysis
Strengths
- Innovative technology platform
- Experienced management team
- Focus on unmet medical needs
- Proprietary technologies
Weaknesses
- Limited financial resources
- Early stage of development
- Dependence on key personnel
- High regulatory hurdles
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion into new therapeutic areas
- Favorable regulatory changes
- Increasing demand for personalized medicine
Threats
- Competition from established pharmaceutical companies
- Clinical trial failures
- Changes in reimbursement policies
- Intellectual property challenges
Competitors and Market Share
Key Competitors
- NVS
- GILD
- BMY
- JNJ
Competitive Landscape
Avalon GloboCare faces intense competition from larger, more established pharmaceutical companies with greater resources. Its competitive advantage lies in its innovative technologies and focus on specific therapeutic areas.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been primarily through research and development and partnerships.
Future Projections: Future growth is dependent on successful clinical trials and commercialization of its product candidates. Analyst estimates vary widely.
Recent Initiatives: Recent initiatives include advancing clinical trials for AVA-011 and expanding its exosome technology platform.
Summary
Avalon GloboCare is an early-stage biopharmaceutical company with innovative technologies and a focus on unmet medical needs. The company faces significant challenges, including limited financial resources and competition from larger players. Successful clinical trials and partnerships are crucial for its future growth. Investors should closely monitor its financial performance and clinical trial progress.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Third-party financial data providers (e.g., Yahoo Finance, Google Finance)
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. The data is based on publicly available information and may not be entirely accurate or complete. Invest at your own risk.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Avalon GloboCare Corp.
Exchange NASDAQ | Headquaters Freehold, NJ, United States | ||
IPO Launch date 2016-12-06 | CEO, President & Director Dr. David K. Jin M.D., Ph.D. | ||
Sector Real Estate | Industry Real Estate Services | Full time employees 4 | Website https://www.avalon-globocare.com |
Full time employees 4 | Website https://www.avalon-globocare.com | ||
Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States. It also distributes the KetoAir device, which is a breathalyzer system that detects acetone levels in exhaled breath; and the AI Nutritionist software program that helps users monitor and manage ketogenic diet and related programs. Avalon GloboCare Corp. was founded in 2015 and is headquartered in Freehold, New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.